Mari Packard

This statement supports the appliance of B. coagulans spores earlier than or through the onset of inflammation to maximise the probiotic advantages in treating inflammatory bowel conditions. In multiple clinical trials, B. Coagulans decreased bloating, vomiting, diarrhea, abdominal pain and stool frequency and elevated the standard of life in patients with diarrhea-predominant irritable bowel syndrome (IBS). In a single study, diarrhea-predominant IBS patients obtained Bacillus coagulans GBI 30...